Stendhal (officially Específicos Stendhal, S.A. de C.V.) is a private Mexican pharmaceutical company established in 1974 that specializes in the identification, development, and commercialization of innovative and high-specialty medications in Latin America. Core Business and Therapeutic Areas The company focuses on innovative medicines rather than generics, specifically targeting high-tech treatments for critical conditions. Its primary therapeutic areas include: Specialty Medicines: HIV/AIDS (antiretrovirals), anti-infective diseases, and neuroscience. Emerging Portfolios: Cardiovascular, metabolic diseases, and oncology (through alliances with partners like Baxter). Orphan and Rare Diseases: Leader in orphan drug therapies, having signed licenses with 10 business partners in 2021 specifically for rare diseases. Primary Care: Distribution and marketing of primary care products across Mexico, Central America, and the Caribbean. Operations and Infrastructure Stendhal operates as a regional powerhouse with a physical presence in 14 countries across Latin America. Headquarters: Located in Mexico City, Mexico. Manufacturing: Maintains a specialized plant in the State of Mexico certified by COFEPRIS (NOM-059-SSA1-2015) and ISO 9001:2015. Services: Offers secondary packaging services for oral solids, injectables, and cold chain medications for national and international clients. Logistics: Distinguished for its advanced market knowledge and sophisticated cold chain storage systems. Corporate Governance and Compliance Acquired by a group of Mexican investors in 1997, the company transitioned into a socially committed organization with a heavy emphasis on ethics. Governance: Led by a Board of Directors consisting of seven members (four proprietary and three independent). Compliance: Features a dedicated "Total Compliance Team" that reports directly to the Board, ensuring adherence to anti-corruption, data protection, and economic competition laws. Awards: Recipient of the transparency award from CETIFARMA (2010) and an ethics award from CONCAMIN (2012). Financial and Personnel Statistics Revenue: Estimated at approximately $51.5 million. Workforce: Employs between 182 and 230 people directly, though some estimates for the broader group range up to 500. Strategic Alliances: A key part of its business model involves partnering with global innovators like Gilead Sciences Inc. to bring advanced therapies to the Latin American market.